Literature DB >> 17998874

Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants.

Hiroshi Asano1, Chih-Yuan Lee, Karen Fox-Talbot, Cheryl M Koh, Melek M Erdinc, Susanne Marschner, Shawn Keil, Raymond P Goodrich, William M Baldwin.   

Abstract

BACKGROUND: Functional leukocytes in blood transfusions can cause alloimmunization. Previous studies have shown that exposure of platelet concentrates to riboflavin and light (Mirasol PRT treatment) causes irreparable modification of nucleic acids. This treatment does not interfere with platelet function but does inhibit a wide range of immunological functions of leukocytes present in platelet concentrates. The current study evaluated the ability of Mirasol treatment to prevent alloimmunization by platelet transfusions in rats.
METHODS: Lewis rats received eight transfusions of untreated or Mirasol-treated platelets containing leukocytes from DA rats. Animals were subsequently challenged with a heart transplant under cyclosporine treatment.
RESULTS: Mirasol treatment caused apoptosis of the leukocytes as measured by annexin V and CD45 staining. Complement split products were deposited on the apoptotic bodies in the platelet pack. The primary and secondary immunoglobulin (Ig) M and IgG responses in rats that received Mirasol-treated platelets were almost completely abolished compared to animals that received untreated platelets. Untreated platelet transfusions elicited strong IgG responses that were associated with rapid rejection of subsequent heart transplants. Rejected hearts contained macrophage infiltrates and C4d deposits. In contrast, no grafts were rejected by recipients transfused with Mirasol-treated platelets. Macrophage infiltrates and C4d deposits were decreased in these grafts. Recipients that were presensitized to untreated platelets were capable of producing a memory response to Mirasol-treated platelets that caused accelerated rejection of subsequent transplants.
CONCLUSIONS: Transfusions of platelets that were treated with riboflavin and ultraviolet light prevented presensitization to transplants. However, Mirasol-treated platelets were immunogenic in presensitized recipients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998874     DOI: 10.1097/01.tp.0000287318.94088.d7

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

Review 1.  Effect of Induced Pluripotent Stem Cell Technology in Blood Banking.

Authors:  Daniele Focosi; Mauro Pistello
Journal:  Stem Cells Transl Med       Date:  2016-01-27       Impact factor: 6.940

2.  A multidisciplinary "think tank": the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium.

Authors:  Cassandra D Josephson; Simone A Glynn; Steve H Kleinman; Morris A Blajchman
Journal:  Transfusion       Date:  2010-10-04       Impact factor: 3.157

3.  The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.

Authors:  Håkon Reikvam; Susanne Marschner; Torunn Oveland Apelseth; Ray Goodrich; Tor Hervig
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

4.  Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.

Authors:  Azucena Castrillo; Marcia Cardoso; Lindsay Rouse
Journal:  Transfus Med Hemother       Date:  2013-01-03       Impact factor: 3.747

5.  Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response.

Authors:  Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Garth H Utter; Cathy Schechterly; Mila Lebedeva; Eva Operskalski; Naomi L Luban; Harvey Alter; Michael P Busch; Sherrill J Slichter; Philip J Norris
Journal:  Transfusion       Date:  2013-06-30       Impact factor: 3.157

6.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

Review 7.  One size will never fit all: the future of research in pediatric transfusion medicine.

Authors:  Cassandra D Josephson; Traci Heath Mondoro; Daniel R Ambruso; Rosa Sanchez; Steven R Sloan; Naomi L C Luban; John A Widness
Journal:  Pediatr Res       Date:  2014-08-13       Impact factor: 3.756

8.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

9.  Role of Riboflavin- and UV Light-Treated Plasma in Prevention of Transfusion-Related Acute Lung Injury.

Authors:  Teresa Jimenez-Marco; Daniel Ruiz-Alderton; Antonia M Bautista-Gili; Enrique Girona-Llobera
Journal:  Transfus Med Hemother       Date:  2014-05-12       Impact factor: 3.747

Review 10.  Improving platelet transfusion safety: biomedical and technical considerations.

Authors:  Olivier Garraud; Fabrice Cognasse; Jean-Daniel Tissot; Patricia Chavarin; Syria Laperche; Pascal Morel; Jean-Jacques Lefrère; Bruno Pozzetto; Miguel Lozano; Neil Blumberg; Jean-Claude Osselaer
Journal:  Blood Transfus       Date:  2015-11-16       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.